Massive study compares four diabetes drugs for heart safety

NCT ID NCT05214573

Completed Knowledge-focused Sponsor: Mayo Clinic Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study looked at health records from over 386,000 adults with type 2 diabetes and moderate heart disease risk. Researchers compared four common second-line diabetes drugs to see which ones were linked to fewer heart attacks, strokes, and other complications. They also asked patients which treatment outcomes mattered most to them. The goal is to help doctors and patients choose the best medication based on real-world data.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: glucagon-like peptide-1 receptor agonists, SGLT2 inhibitors, DPP-4 inhibitors, sulfonylureas
What this could lead to: If successful, this could help doctors choose the safest second-line diabetes drug for patients with moderate heart disease risk.
What could go wrong: This is an observational study using past data, not a controlled trial, so results may be less reliable. It cannot prove cause and effect.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CARDIAC DISEASE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

cardiovascular disorder diabetes mellitus heart disorder type 2 diabetes mellitus

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CARDIAC DISEASE TYPE 2 DIABETES

Contacts and locations

Locations

Mayo Clinic Rochester

Rochester, Minnesota, 55905, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.